A5043134099- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Breast Implant and Reconstruction
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer and Skin Lesions
- Cancer Cells and Metastasis
- Chronic Lymphocytic Leukemia Research
- Medical Imaging Techniques and Applications
- Actinomycetales infections and treatment
- Growth Hormone and Insulin-like Growth Factors
- Molecular Biology Techniques and Applications
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- Liver Disease and Transplantation
- RNA modifications and cancer
Mayo Clinic Hospital
2008-2024
WinnMed
2011-2023
Mayo Clinic in Florida
2008-2023
Mayo Clinic in Arizona
2012-2021
Institut Jules Bordet
2015-2019
Novartis (Switzerland)
2015-2019
Johns Hopkins University
2019
Dana-Farber Cancer Institute
2019
Chinese Academy of Medical Sciences & Peking Union Medical College
2019
European Institute of Oncology
2019
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
Advanced cholangiocarcinoma continues to harbor a difficult prognosis and therapeutic options have been limited. During the course of clinical trial whole genomic sequencing seeking druggable targets, we examined six patients with advanced cholangiocarcinoma. Integrated genome-wide transcriptome sequence analyses were performed on tumors from advanced, sporadic intrahepatic (SIC) identify potential therapeutically actionable events. Among somatic events captured in our analysis, uncovered...
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity residual disease detection during or after completion in patients with nonmetastatic cancer. To address this gap and to improve minute quantities plasma, we have developed targeted digital sequencing (TARDIS) multiplexed patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 16 known mutations,...
Purpose To develop a genomic signature that predicts benefit from trastuzumab in human epidermal growth factor receptor 2–positive breast cancer. Patients and Methods DASL technology was used to quantify mRNA samples 1,282 patients enrolled onto the Combination Chemotherapy With or Without Trastuzumab Treating Women Breast Cancer (North Central Treatment Group N9831 [NCCTG-N9831]) adjuvant trial. Cox proportional hazard ratios (HRs), adjusted for significant clinicopathologic risk factors,...
Folate receptor alpha (FOLR1) has been identified as a potential prognostic and therapeutic target in number of cancers. A correlation shown between intense overexpression FOLR1 breast tumors poor prognosis, yet there is limited examination the distribution across clinically relevant cancer subtypes. To explore this further, we used RNA-seq data from multiple patient cohorts to analyze mRNA subtypes comprised estrogen positive (ER+), human epidermal growth factor (HER2+), triple negative...
// Michael T. Barrett 1 , Karen S. Anderson 2 Elizabeth Lenkiewicz Mariacarla Andreozzi Heather E. Cunliffe 3 Christine L. Klassen 4 Amylou C. Dueck 5 Ann McCullough 6 Srikanth K. Reddy 7 Ramesh Ramanathan 8 Donald W. Northfelt Barbara A. Pockaj Department of Research, Mayo Clinic in Arizona, Scottsdale, United States America Biodesign Institute, Arizona State University, Tempe, Pathology, Dunedin School Medicine, University Otago, Dunedin, New Zealand Division General Surgery, Section...
It has been suggested that PTEN, a negative regulator of PI3K/AKT signaling, is involved in tumor sensitivity to trastuzumab. We investigated the association between PTEN protein expression and disease-free survival (DFS) patients randomly assigned receive chemotherapy alone (arm A) or with sequential B) concurrent trastuzumab C) phase III early-stage human epidermal growth factor receptor 2 (HER2) -positive trial-North Central Cancer Treatment Group (NCCTG) N9831.The intensity percentage...
Coccidioides spp. are dimorphic fungal pathogens endemic to the semiarid regions of North, Central, and South America. Currently, direct smear culture most common means identifying While these methods offer relatively sensitive specific detecting spp., growth in may take up 3 weeks, potentially delaying diagnosis initiation appropriate antifungal therapy. In addition, organism represents a significant safety risk laboratory personnel. The need for rapid safe diagnosing coccidioidomycosis...
Elevated PD-L1 expression on tumor cells, a context associated with an adaptive immune response, has been linked to the total burden of copy number variants (CNVs) in aneuploid tumors, microsatellite instability (MSI), and specific genomic driver lesions, including loss PTEN, MYC amplification, activating mutations oncogenes such as KRAS PIK3CA. Triple-negative breast cancers (TNBCs) typically have high levels CNVs diverse lesions their genomes. Thus, there is significant interest exploiting...
The 2007 American Society of Clinical Oncology and College Pathologists (ASCO/CAP) joint guidelines defined criteria for HER2 positivity tumors that modified those the US Food Drug Administration (FDA), causing some confusion uncertainty among clinicians. Using data from HER2-positive breast cancer adjuvant trial N9831, we compared eligibility patients who met both criteria, disease-free survival (DFS) was assessed by Cox proportional hazards regression. number in N9831 retrospectively...
As invasive mucormycosis (IM) numbers rise, clinicians suspect prior voriconazole worsens IM incidence and severity, believe combination anti-fungal therapy improves survival. To compare the cumulative (CI), severity mortality of in eras immediately before after commercial availability all cases from 1995 to 2011 were analysed across four risk-groups (hematologic/oncologic malignancy (H/O), stem cell transplantation (SCT), solid organ (SOT) other), two eras, E1 (1995-2003) E2, (2004-2011)....
Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit adjuvant trastuzumab in patients early-stage breast cancer. To further explore this relationship, we investigated associations between MYC amplification disease-free survival (DFS) a similar HER2-positive cancer trial-North Central Cancer Treatment...
The role and clinical value of ERβ1 expression is controversial recent data demonstrates that many ERβ antibodies are insensitive and/or non-specific. Therefore, we sought to comprehensively characterize across all sub-types breast cancer using a validated antibody determine the roles this receptor in mediating response multiple forms endocrine therapy both presence absence ERα expression. Nuclear cytoplasmic patterns were analyzed three patient cohorts, including retrospective analysis...
Formalin fixed paraffin embedded (FFPE) tissues are a vast resource of annotated clinical samples. As such, they represent highly desirable and informative materials for the application high definition genomics improved patient management to advance development personalized therapeutics. However, limitation FFPE is variable quality DNA extracted analyses. Furthermore, admixtures non-tumor polyclonal neoplastic cell populations limit number biopsies that can be studied make it difficult...
Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination gemcitabine was superior to erlotinib, but the clinical relevance is uncertain given limited role of monotherapy.A significantly longer overall survival observed patients receiving dual EGFR-directed therapy.The resulted increased toxicity.Gemcitabine active advanced pancreatic adenocarcinoma. The an oral (EGFR) inhibitor, shown modestly prolong when compared alone. North Central...